{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:19:01Z","timestamp":1792196341678,"version":"4.4.0"},"reference-count":84,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:00:00Z","timestamp":1666483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Romanian Ministry of Education and Research, CNCS-UEFISCDI","award":["PN-III-P1-1.1-TE-2019-0370"],"award-info":[{"award-number":["PN-III-P1-1.1-TE-2019-0370"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hemostasis is a physiological process critical for survival. Meanwhile, thrombosis is amongst the leading causes of death worldwide, making antithrombotic therapy one of the most crucial aspects of modern medicine. Although antithrombotic therapy has progressed tremendously over the years, it remains far from ideal, and this is mainly due to the incomplete understanding of the exceptionally complex structural and functional properties of platelets. However, advances in biochemistry, molecular biology, and the advent of \u2018omics\u2019 continue to provide crucial information for our understanding of the complex structure and function of platelets, their interactions with the coagulation system, and their role in hemostasis and thrombosis. In this review, we provide a comprehensive view of the complex role that platelets play in hemostasis and thrombosis, and we discuss the major clinical implications of these fundamental blood components, with a focus on hemostatic platelet-related disorders and existing and emerging antithrombotic therapies. We also emphasize a number of questions that remain to be answered, and we identify hotspots for future research.<\/jats:p>","DOI":"10.3390\/ijms232112772","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T04:40:36Z","timestamp":1666586436000},"page":"12772","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":289,"title":["Platelets and Their Role in Hemostasis and Thrombosis\u2014From Physiology to Pathophysiology and Therapeutic Implications"],"prefix":"10.3390","volume":"23","author":[{"given":"Alina","family":"Scridon","sequence":"first","affiliation":[{"name":"Physiology Department, Center for Advanced Medical and Pharmaceutical Research, University of Medicine, Pharmacy, Science and Technology \u201cGeorge Emil Palade\u201d of T\u00e2rgu Mure\u0219, 540142 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rumbaut, R.E., and Thiagarajan, P. (2010). Chapter 2, General Characteristics of Platelets. Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis, Morgan & Claypool Life Sciences.","DOI":"10.4199\/C00007ED1V01Y201002ISP004"},{"key":"ref_2","unstructured":"Michelson, A.D. (2019). The Role of Platelets in Inflammation in Platelets, Academic Press. [4th ed.]."},{"key":"ref_3","unstructured":"Michelson, A.D. (2019). Therapeutic Platelet-Rich Plasma in Wound Healing in Platelets, Academic Press. [4th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.12688\/f1000research.11437.1","article-title":"Therapeutic potential of systemic brain rejuvenation strategies for neurodegenerative disease","volume":"6","author":"Horowitz","year":"2017","journal-title":"F1000Research"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Aquino-Dom\u00ednguez, A.S., Romero-Tlalolini, M.L.A., Torres-Aguilar, H., and Aguilar-Ruiz, S.R. (2021). Recent advances in the discovery and function of antimicrobial molecules in platelets. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910230"},{"key":"ref_6","unstructured":"Michelson, A.D. (2019). The Role of Platelets in Antimicrobial Host Defense in Platelets, Academic Press. [4th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3389\/fimmu.2019.01590","article-title":"The human platelet as an innate immune cell: Interactions between activated platelets and the complement System","volume":"10","author":"Eriksson","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1749-6632.1983.tb35221.x","article-title":"Biochemical and electrostatic considerations in primary platelet aggregation","volume":"416","author":"Coller","year":"1983","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e00085","DOI":"10.1002\/phy2.85","article-title":"Pericellular Ca(2+) recycling potentiates thrombin-evoked Ca(2+) signals in human platelets","volume":"1","author":"Sage","year":"2013","journal-title":"Physiol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nm.3770","article-title":"The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling","volume":"21","author":"Grozovsky","year":"2015","journal-title":"Nat. Med."},{"key":"ref_11","unstructured":"Michelson, A.D. (2019). The Structure of Resting and Activated Platelets in Platelets, Academic Press. [4th ed.]."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0037-1616227","article-title":"Protease-activated receptors in vascular biology","volume":"86","author":"Coughlin","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1182\/blood.V91.11.4152","article-title":"Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin","volume":"91","author":"Ishihara","year":"1998","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/CIRCULATIONAHA.107.696732","article-title":"Bedside evaluation of thienopyridine antiplatelet therapy","volume":"119","author":"Price","year":"2009","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","article-title":"Platelet alpha-granules: Basic biology and clinical correlates","volume":"23","author":"Blair","year":"2009","journal-title":"Blood Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/CIRCRESAHA.114.301598","article-title":"What can proteomics tell us about platelets?","volume":"114","author":"Burkhart","year":"2014","journal-title":"Circ. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2011-01-330910","article-title":"Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet \u03b1-granules","volume":"118","author":"Kamykowski","year":"2011","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1084\/jem.187.3.329","article-title":"Adhesion of activated platelets to endothelial cells: Evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha","volume":"187","author":"Bombeli","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/j.1538-7836.2009.03444.x","article-title":"Integrin alpha2beta1 induces phosphorylation-dependent and phosphorylation-independent activation of phospholipase Cgamma2 in platelets: Role of Src kinase and Rac GTPase","volume":"7","author":"Guidetti","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1050-1738(01)00073-1","article-title":"A role for the actin cytoskeleton in the initiation and maintenance of store-mediated calcium entry in human platelets","volume":"10","author":"Rosado","year":"2000","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2008.01.001","article-title":"Thromboxane A2: Physiology\/pathophysiology, cellular signal transduction and pharmacology","volume":"118","author":"Nakahata","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref_22","unstructured":"Michelson, A.D. (2019). Platelet Signal Transduction in Platelets, Academic Press. [4th ed.]."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/10409230903193307","article-title":"The ins and outs of phospholipid asymmetry in the plasma membrane: Roles in health and disease","volume":"44","author":"Fadeel","year":"2009","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2010-01-261669","article-title":"Procoagulant platelets: Are they necrotic?","volume":"116","author":"Jackson","year":"2010","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0037-1613209","article-title":"Platelet activation and blood coagulation","volume":"88","author":"Heemskerk","year":"2002","journal-title":"Thromb. Haemost."},{"key":"ref_26","unstructured":"Michelson, A.D. (2019). Integrin \u03b1IIb\u03b23 in Platelets, Academic Press. [4th ed.]."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100733","DOI":"10.1016\/j.blre.2020.100733","article-title":"Interplay between platelets and coagulation","volume":"46","author":"Sang","year":"2021","journal-title":"Blood Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood.V96.13.4246","article-title":"Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway","volume":"96","author":"Quek","year":"2000","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nrm2871","article-title":"The final steps of integrin activation: The end game","volume":"11","author":"Shattil","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/BF03022247","article-title":"From normal to pathological hemostasis","volume":"53","author":"Lasne","year":"2006","journal-title":"Can. J. Anaesth."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1182\/blood-2010-09-307306","article-title":"Tissue factor expression on platelets is a dynamic event","volume":"116","author":"Camera","year":"2010","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/aps.2013.188","article-title":"Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets","volume":"35","author":"Wang","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2009-08-237719","article-title":"Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms","volume":"115","author":"Duckers","year":"2010","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1172\/JCI112560","article-title":"Transplantation of normal bone marrow into a pig with severe von Willebrand\u2019s disease","volume":"78","author":"Bowie","year":"1986","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1160\/TH04-09-0584","article-title":"Glycoprotein VI is associated with GPIb-IX-V on the membrane of resting and activated platelets","volume":"93","author":"Arthur","year":"2005","journal-title":"Thromb. Haemost."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/09537104.2019.1581922","article-title":"Platelets compensate for poor thrombin generation in type 3 von Willebrand disease","volume":"31","author":"Szanto","year":"2020","journal-title":"Platelets"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11239-011-0600-y","article-title":"In vivo real-time two-photon microscopic imaging of platelet aggregation induced by selective laser irradiation to the endothelium created in the beta-actin-green fluorescent protein transgenic mice","volume":"32","author":"Koike","year":"2011","journal-title":"J. Thromb. Thrombolysis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jth.12491","article-title":"Thrombin generation and fibrin formation under flow on biomimetic tissue factor-rich surfaces","volume":"12","author":"Puls","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.jacc.2004.12.075","article-title":"Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism","volume":"45","author":"Chirinos","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"Stark","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.phrs.2016.04.001","article-title":"Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin effects in mouse model","volume":"107","author":"Tarantino","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1055\/s-0037-1615817","article-title":"A Systematic Review on the Use of Aspirin in the Prevention of Deep Vein Thrombosis in Major Elective Lower Limb Orthopedic Surgery: An Update from the Past 3 Years","volume":"3","author":"Mistry","year":"2017","journal-title":"Surg. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: The INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators, Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S., Pfeffer, M., Hohnloser, S., and Yusuf, S. (2006). Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet, 367, 1903\u20131912.","DOI":"10.1016\/S0140-6736(06)68845-4"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_49","unstructured":"ClinicalTrials.gov (2022, August 16). Comparative Effectiveness of Pulmonary Embolism Prevention after Hip and Knee Replacement (PEPPER), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02810704."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.atherosclerosis.2020.07.008","article-title":"Platelets and coagulation factors: Established and novel roles in atherosclerosis and atherothrombosis","volume":"307","author":"Koenen","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e009451","DOI":"10.1161\/JAHA.118.009451","article-title":"Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post-Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51","volume":"8","author":"Gibson","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_53","unstructured":"(1994). Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet, 343, 499\u2013503."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s11239-020-02093-9","article-title":"Edoxaban affects TRAP-dependent platelet aggregation","volume":"49","author":"Nehaj","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1515\/cclm-2013-0936","article-title":"Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests","volume":"52","author":"Eller","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jns.2015.07.031","article-title":"Impact of dabigatran on platelet function and fibrinolysis","volume":"357","author":"Tsantes","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1076029614564209","article-title":"Laboratory assessment of the anticoagulant activity of dabigatran","volume":"21","author":"Kyriakou","year":"2015","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.amjcard.2013.08.027","article-title":"Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors","volume":"112","author":"Artang","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_59","first-page":"j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"Sterne","year":"2017","journal-title":"BMJ"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"367ra168","DOI":"10.1126\/scitranslmed.aad6712","article-title":"Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis","volume":"8","author":"Petzold","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/jth.13595","article-title":"Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation","volume":"15","author":"Achilles","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/jth.14386","article-title":"Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration\u2014results from a diabetes animal model","volume":"17","author":"Scridon","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.thromres.2015.10.038","article-title":"TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran","volume":"138","author":"Olivier","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/rth2.12454","article-title":"Protease-activated receptors: An illustrated review","volume":"5","author":"Han","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_65","first-page":"P0518","article-title":"Antithrombotic mechanism of action of BAY 59-7939\u2014A novel, oral, direct factor Xa inhibitor","volume":"3","author":"Fareed","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11239-017-1495-z","article-title":"Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation","volume":"43","author":"Steppich","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1074248415578172","article-title":"Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies","volume":"20","author":"Perzborn","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Pujadas-Mestres, L., Lopez-Vilchez, I., Arellano-Rodrigo, E., Reverter, J.C., Lopez-Farre, A., Diaz-Ricart, M., Badimon, J.J., and Escolar, G. (2017). Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171486"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"0188","DOI":"10.1007\/s100470200035","article-title":"Platelet aggregation in patients taking anticoagulants after valvular surgery: Evaluation by a laser light-scattering method","volume":"5","author":"Kawahito","year":"2002","journal-title":"J. Artif. Organs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0049-3848(92)90309-X","article-title":"Antiplatelet actions of some coumarin compounds isolated from plant sources","volume":"66","author":"Teng","year":"1992","journal-title":"Thromb. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1182\/blood-2010-09-307751","article-title":"Heparin promotes platelet responsiveness by potentiating \u03b1IIb\u03b23-mediated outside-in signaling","volume":"117","author":"Gao","year":"2011","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0609.1989.tb00290.x","article-title":"The mechanism of heparin-induced platelet aggregation","volume":"43","author":"Chong","year":"1989","journal-title":"Eur. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/FTD.0000000000000247","article-title":"Laboratory Monitoring: A Turning Point in the Use of New Oral Anticoagulants","volume":"38","author":"Scridon","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/europace\/euz156","article-title":"Prediction of ventricular arrhythmias in patients with a spontaneous Brugada type 1 pattern: The key is in the electrocardiogram","volume":"21","author":"Baranchuk","year":"2019","journal-title":"Europace"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Li, S., Tarlac, V., and Hamilton, J.R. (2019). Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225629"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.acvd.2017.11.001","article-title":"Atrial fibrillation: Neurogenic or myogenic?","volume":"111","author":"Scridon","year":"2018","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","author":"Graham","year":"2015","journal-title":"Circulation"},{"key":"ref_79","first-page":"405","article-title":"Left atrial endocardial fibrosis and intra-atrial thrombosis\u2014Landmarks of left atrial remodeling in rats with spontaneous atrial tachyarrhythmias","volume":"54","author":"Scridon","year":"2013","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/1753-0407.12580","article-title":"Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus","volume":"10","author":"Scridon","year":"2018","journal-title":"J. Diabetes"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","article-title":"Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)","volume":"61","author":"Patel","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ahj.2014.09.006","article-title":"Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"169","author":"Granger","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/eurheartj\/ehq023","article-title":"Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel","volume":"31","author":"Sibbing","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"798486","DOI":"10.1155\/2015\/798486","article-title":"Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials)","volume":"2015","author":"Martischnig","year":"2015","journal-title":"Biomed. Res. Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/12772\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:01:19Z","timestamp":1760144479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/12772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,23]]},"references-count":84,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijms232112772"],"URL":"https:\/\/doi.org\/10.3390\/ijms232112772","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,23]]}}}